Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5797 - Adult rhabdomyosarcoma in Tunisia : Clinical presentation, treatment and outcome

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cancer Prevention

Tumour Site

Sarcoma

Presenters

Mariem Saadi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

M. Saadi1, D. Tajina1, F. Letaief-Ksontini1, K. Meddeb1, A. Gabsi2, Y. Yahyaoui1, A. Mokrani1, M. Ayadi1, N. Chraiet1, H. Rais1, A. Mezlini1

Author affiliations

  • 1 Medical Oncology, Salah Azaiez Institute, 1006 - Tunis/TN
  • 2 Medecine, Salah Azaiez Institute, 1006 - Tunis/TN
More

Resources

Abstract 5797

Background

We aimed to describe clinico-pathological features and outcomes of Rahbdomyosarcoma (RMS) in Tunisia.

Methods

We assembled a retrospective cohort of 47 patients aged 18 or older diagnosed with, and treated for RMS at our institute between 1994 and 2013. Patient's characteristics, tumor variables and treatment outcomes were evaluated. Tumors were classified according to the Intergroup RMS Study (IRS) staging.

Results

Median age was 39 and 66% were male. At presentation, 33 had localised disease and 14 metastatic. Metastasis site was lung in 17% of cases. Sixteen patients had node positive disease. Median tumor size was 9 cm. Patients presented with swelling or palpable mass in 63.8% of cases, pain in 17%, exophthalmia in 6.4% and bleeding in 4.3%. Less common clinical presentations were functional impairment, cranial nerve palsies, superior vena cava syndrome and nasal obstruction seen in one case each. Tumor site was extremities in 40.4% of cases, trunk in 23.4%, head and neck in 19.1% and genito-urinary tract in 17%. According to favorable/unfavorable prognostic location, tumor site was unfavorable in 65.9% of cases and favorable in 33.9%. RMS histologic subtype was pleomorphic in 36.2% of patients, embryonic in 25.5%, not mentioned in 23.4%, alveolar in 12.8% and combination of embryonic and alveolar in 2.1%. Among 38 patients who underwent surgery, 40.4% had complete resection (IRS stage I). Chemotherapy was adjuvant in 4 patients, neoadjuvant in 6 and 1st line in 13 with a median number of cycle of 3 in each schedule. Radiotherapy (RT) was adjuvant in 19.1% of cases and symptomatic/palliative in 21.1%. Median dose of adjuvant RT was 55 Gray. Median progression free survival after adjuvant treatment was 4.5 months, 47.1% relapsed locally, 35.3% developed distant metastasis and 17.6% presented local recurrence with distant metastases. Five year overall survival (OS) was 46% for localised RMS and 40% for metastatic disease. Among all studied factors, non operated patients and those under 30 years old had worse OS with p values of 0.005 and 0 respectively.

Conclusions

Adults with RMS have poor prognosis. All patients should therefore undergo multimodality treatment comprising of surgery, radiation, and chemotherapy to achieve better outcomes.

Clinical trial identification

Legal entity responsible for the study

Amel Mezlini.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.